Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 17, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4,...
-
Dec 16, 2013
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected David Roux as a Director. The appointment of Mr. Roux will fill a...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority,...
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate...
-
Dec 6, 2013
Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the...
-
Nov 25, 2013Advanced Stent Technology to Launch Immediately in the United States
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
-
Nov 22, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Piper Jaffray Healthcare Conference on December 3 in New...
-
Nov 21, 2013
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective...
-
Nov 19, 2013Boston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable MicrocatheterProprietary Shaft Design Enables Better Control In Hard-To-Navigate Vessels
Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX) has received U.S....
-
Nov 19, 2013First System To Selectively Stimulate Targeted Areas Of The Brain To Manage Symptoms of Debilitating Disease
The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment...
-
Nov 15, 2013Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the...
-
Nov 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Nov 1, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of...
-
Oct 31, 2013New Data Announced At TCT 2013 Demonstrate Successful Deployment In All 120 Patients With No Severe Paravalvular Regurgitation At 30 Days
The Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System met a key performance measure in the treatment of symptomatic patients with...
-
Oct 31, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood...
-
Oct 28, 2013
Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...
-
Oct 28, 2013Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve...
-
Oct 24, 2013Jeffrey Capello to Transition Out of CFO Role at Year-End
Boston Scientific Corporation (NYSE: BSX) has initiated a transition plan for its new chief financial officer. Noting a desire to pursue opportunities...
-
Oct 24, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.17 for the third quarter ended...
Oct 23, 2013Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbationsBoston Scientific Corporation (NYSE: BSX) has received China Food and Drug Administration approval for the Alair® Bronchial Thermoplasty System, an...
-
Oct 23, 2013Award Recognizes Innovative S-ICD® System, the World's First and Only Subcutaneous Implantable Defibrillator
The Boston Scientific Corporation (NYSE: BSX) S-ICD® System has received the Prix Galien USA 2013 Award for Best Medical Technology. The S-ICD...
-
Oct 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2013 on
-
Oct 9, 2013MAJESTIC Trial To Study Self-Expanding DES System Designed To Treat Superficial Femoral Artery (SFA) Lesions
Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed...
-
Oct 8, 2013University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are...
-
Oct 8, 2013Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session
The Boston Scientific (NYSE: BSX) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete...
-
Sep 17, 2013
ORBUSNEICH, BOSTON SCIENTIFIC SETTLE PATENT LITIGATION Fort Lauderdale, Fla. and Natick, Mass. (September 17, 2013) -- OrbusNeich Medical Inc. and Boston Scientific Corporation (NYSE: BSX) have...
-
Sep 17, 2013
Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX) today officially...
Sep 17, 2013REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves CourseBOSTON SCIENTIFIC REPORTS favorable SIX-MONTH RESULTS from LOTUS™ valve system clinical trial REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Natick, Mass. (Sept. 17,...
Sep 12, 2013In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE:...
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than HoursA breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years,...
Sep 4, 2013Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Stifel Nicolaus Healthcare Conference on Sept. 11 in Boston. Jeff...
- Sep 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference on Sept. 9 in New York....
Aug 21, 2013Shanghai, China (August 21, 2013) - The first patient implants of the Boston Scientific Corporation (NYSE: BSX) COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully...
Aug 21, 2013Boston Scientific Corporation (NYSE: BSX) continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA)...
-
Aug 19, 2013Innovative Bare Metal Stent Designed to Treat Peripheral Artery Disease
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial...
-
Aug 13, 2013
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the...
-
Aug 8, 2013
Boston Scientific Corporation (NYSE: BSX) announces the pricing of a public offering of $1.05 billion aggregate principal amount of its senior notes...
-
Jul 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June...
-
Jul 24, 2013
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a...
-
Jul 24, 2013Next generation intravascular ultrasound catheter improves image quality and deliverability
The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its...
-
Jul 19, 2013First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™...
-
Jul 12, 2013Device Facilitates Delivery of Interventional Devices in Complex PCI Procedures
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™...
-
Jul 11, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific...
-
Jun 26, 2013
Paris (June 26, 2013) – The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIOTM pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition...
-
Jun 25, 2013
Paris (June 25, 2013) – Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
Paris (June 24, 2013) – The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related...
-
Jun 18, 2013VANTAGE Study Interim Data Presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a...
-
Jun 17, 2013First Implant of Company's Vercise Deep Brain Stimulation Device Designed to Treat Parkinson's
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...